Back to top
more

ProPhase Labs (PRPH)

(Delayed Data from NSDQ)

$5.05 USD

5.05
32,777

+0.13 (2.64%)

Updated May 10, 2024 04:00 PM ET

After-Market: $5.05 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PRPH

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

ProPhase Labs, Inc. [PRPH]

Reports for Purchase

Showing records 21 - 40 ( 50 total )

Company: ProPhase Labs, Inc.

Industry: Medical - Drugs

Record: 21

12/20/2022

Company Report

Pages: 6

Novel Esophageal Cancer Test Acquired; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 12.50

Research Provided by a Third Party

Company: ProPhase Labs, Inc.

Industry: Medical - Drugs

Record: 22

11/11/2022

Company Report

Pages: 6

3Q22 Financial Results Reported; Reiterate Buy; Modulating PT to $15

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 12.50

Research Provided by a Third Party

Company: ProPhase Labs, Inc.

Industry: Medical - Drugs

Record: 23

10/20/2022

Company Report

Pages: 6

Collaboration Inked to Drive Genomic Sequencing Business; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 12.50

Research Provided by a Third Party

Company: ProPhase Labs, Inc.

Industry: Medical - Drugs

Record: 24

09/07/2022

Company Report

Pages: 3

Termination of Coverage

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: ProPhase Labs, Inc.

Industry: Medical - Drugs

Record: 25

08/15/2022

Company Report

Pages: 6

Solid Performance in 2Q22; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 12.50

Research Provided by a Third Party

Company: ProPhase Labs, Inc.

Industry: Medical - Drugs

Record: 26

07/27/2022

Company Report

Pages: 5

Novel Cancer Compounds In-Licensed; Stock Repurchase Authorized; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 5.00

Research Provided by a Third Party

Company: ProPhase Labs, Inc.

Industry: Medical - Drugs

Record: 27

07/21/2022

Company Report

Pages: 5

Is ProPhase Now an Oncology Company? If You Read The Press Release – What’s a Co-Therapy? Lowering Our Rating from Neutral to Sell

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: ProPhase Labs, Inc.

Industry: Medical - Drugs

Record: 28

06/29/2022

Company Report

Pages: 5

ProPhase BioPharma Established for Development of Novel Drugs; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 5.00

Research Provided by a Third Party

Company: ProPhase Labs, Inc.

Industry: Medical - Drugs

Record: 29

06/14/2022

Company Report

Pages: 5

Laboratory and Clinical Testing Capabilities Expanded; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 5.00

Research Provided by a Third Party

Company: ProPhase Labs, Inc.

Industry: Medical - Drugs

Record: 30

05/16/2022

Company Report

Pages: 6

New Record Performance in 1Q22; Reiterate Buy; Modulating PT to $14

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 12.50

Research Provided by a Third Party

Company: ProPhase Labs, Inc.

Industry: Medical - Drugs

Record: 31

04/01/2022

Company Report

Pages: 5

Buy: Reiterate Buy, Raise Price Target to $2.00

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: ProPhase Labs, Inc.

Industry: Medical - Drugs

Record: 32

03/31/2022

Company Report

Pages: 5

Record Performance in 2021; Reiterate Buy; Raising PT to $16

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 5.00

Research Provided by a Third Party

Company: ProPhase Labs, Inc.

Industry: Medical - Drugs

Record: 33

02/16/2022

Company Report

Pages: 5

A Special Dividend? Sounds Nice but Does it Make Sense?

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: ProPhase Labs, Inc.

Industry: Medical - Drugs

Record: 34

01/14/2022

Company Report

Pages: 5

Record Testing Volume in 4Q21; Reiterate Buy; Raise PT to $15

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 5.00

Research Provided by a Third Party

Company: ProPhase Labs, Inc.

Industry: Medical - Drugs

Record: 35

12/20/2021

Company Report

Pages: 29

Initiating at Buy and $12 Price Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 35.00

Research Provided by a Third Party

Company: ProPhase Labs, Inc.

Industry: Medical - Drugs

Record: 36

11/12/2021

Company Report

Pages: 6

ProPhase Growth Appears to Have Stalled

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: ProPhase Labs, Inc.

Industry: Medical - Drugs

Record: 37

10/13/2021

Company Report

Pages: 6

Lowering to Neutral - ProPhase Preannounces Another Miss

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: ProPhase Labs, Inc.

Industry: Medical - Drugs

Record: 38

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for PRPH

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: ProPhase Labs, Inc.

Industry: Medical - Drugs

Record: 39

09/08/2021

Company Report

Pages: 5

BUY: Stock Buyback Announced?

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: ProPhase Labs, Inc.

Industry: Medical - Drugs

Record: 40

09/08/2021

Company Report

Pages: 5

BUY: Stock Buyback Announced?

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party